High dose Losartan and ACE gene polymorphism in IgA nephritis

Background/aims Several studies have reported varying results of the influence of ACE gene on ACEI/ARB therapy. The efficacy of high dose ARB and its influence on ACE gene have not been explored. This is a 6 year randomised trial in IgA nephritis comparing high dose ARB (Losartan 200 mg/day) with no...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Genomic medicine 2008-12, Vol.2 (3-4), p.83-91
Hauptverfasser: Woo, Keng-Thye, Chan, Choong-Meng, Choong, Hui-Lin, Tan, Han-Kim, Foo, Marjorie, Lee, Evan J. C., Tan, Chorh-Chuan, Lee, Grace S. L., Tan, Seng-Hoe, Vathsala, A., Lim, Cheng-Hong, Chiang, Gilbert S. C., Fook-Chong, Stephanie, Yi, Zhao, Tan, H. B., Wong, Kok-Seng
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 91
container_issue 3-4
container_start_page 83
container_title Genomic medicine
container_volume 2
creator Woo, Keng-Thye
Chan, Choong-Meng
Choong, Hui-Lin
Tan, Han-Kim
Foo, Marjorie
Lee, Evan J. C.
Tan, Chorh-Chuan
Lee, Grace S. L.
Tan, Seng-Hoe
Vathsala, A.
Lim, Cheng-Hong
Chiang, Gilbert S. C.
Fook-Chong, Stephanie
Yi, Zhao
Tan, H. B.
Wong, Kok-Seng
description Background/aims Several studies have reported varying results of the influence of ACE gene on ACEI/ARB therapy. The efficacy of high dose ARB and its influence on ACE gene have not been explored. This is a 6 year randomised trial in IgA nephritis comparing high dose ARB (Losartan 200 mg/day) with normal dose ARB (Losartan 100 mg/day), normal dose ACEI (20 mg/day) and low dose ACEI (10 mg/day). Results Patients on high dose ARB had significantly lower proteinuria, 1.0 ± 0.8 gm/day compared to 1.7 ± 1.0 g/day in the other groups ( P  = 0.0005). The loss in eGFR was 0.7 ml min −1 year −1 for high dose ARB compared to 3.2–3.5 ml min −1 year −1 for the other three groups ( P  = 0.0005). There were more patients on high dose ARB with improvement in eGFR compared to other three groups ( P  
doi_str_mv 10.1007/s11568-009-9030-8
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2694861</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733224259</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3848-9c2a36d73e5597da7604e10fa497cf6c26230455bccf4e14f5be06b33775a5263</originalsourceid><addsrcrecordid>eNp1kUtLAzEYRYMovn-AGwm4cDWadyYLhVJ8QcGNrkOayUwjM8mYtIL_3kiLL3CVwD3fTT4OACcYXWCE5GXGmIu6QkhVClFU1VtgH9cSV1Ixsv11p2wPHOT8ghCXHMldsIcVxUqIeh9c3ftuAZuYHZzFbNLSBGhCAyfTG9i54OAY-_chpnHh8wB9gA_dBAY3LpJf-nwEdlrTZ3e8OQ_B8-3N0_S-mj3ePUwns8rSmtWVssRQ0UjqOFeyMVIg5jBqDVPStsISQShinM-tbUvAWj53SMwplZIbTgQ9BNfr3nE1H1xjXVgm0-sx-cGkdx2N17-T4Be6i2-aCMVqgUvB-aYgxdeVy0s9-Gxd35vg4iprSSkhjHBVyLM_5EtcpVC201hSLJXCnBYKrymbYs7JtV9_wUh_utFrN7q40Z9udF1mTn8u8T2xkVEAsgZyiULn0o-n_239AEb9mEU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1731799153</pqid></control><display><type>article</type><title>High dose Losartan and ACE gene polymorphism in IgA nephritis</title><source>SpringerLink Journals</source><source>Springer Nature OA Free Journals</source><source>PubMed Central</source><creator>Woo, Keng-Thye ; Chan, Choong-Meng ; Choong, Hui-Lin ; Tan, Han-Kim ; Foo, Marjorie ; Lee, Evan J. C. ; Tan, Chorh-Chuan ; Lee, Grace S. L. ; Tan, Seng-Hoe ; Vathsala, A. ; Lim, Cheng-Hong ; Chiang, Gilbert S. C. ; Fook-Chong, Stephanie ; Yi, Zhao ; Tan, H. B. ; Wong, Kok-Seng</creator><creatorcontrib>Woo, Keng-Thye ; Chan, Choong-Meng ; Choong, Hui-Lin ; Tan, Han-Kim ; Foo, Marjorie ; Lee, Evan J. C. ; Tan, Chorh-Chuan ; Lee, Grace S. L. ; Tan, Seng-Hoe ; Vathsala, A. ; Lim, Cheng-Hong ; Chiang, Gilbert S. C. ; Fook-Chong, Stephanie ; Yi, Zhao ; Tan, H. B. ; Wong, Kok-Seng</creatorcontrib><description>Background/aims Several studies have reported varying results of the influence of ACE gene on ACEI/ARB therapy. The efficacy of high dose ARB and its influence on ACE gene have not been explored. This is a 6 year randomised trial in IgA nephritis comparing high dose ARB (Losartan 200 mg/day) with normal dose ARB (Losartan 100 mg/day), normal dose ACEI (20 mg/day) and low dose ACEI (10 mg/day). Results Patients on high dose ARB had significantly lower proteinuria, 1.0 ± 0.8 gm/day compared to 1.7 ± 1.0 g/day in the other groups ( P  = 0.0005). The loss in eGFR was 0.7 ml min −1 year −1 for high dose ARB compared to 3.2–3.5 ml min −1 year −1 for the other three groups ( P  = 0.0005). There were more patients on high dose ARB with improvement in eGFR compared to other three groups ( P  &lt; 0.001). Comparing patients with the three ACE genotypes DD, ID and II, all three groups responded well to therapy with decrease in proteinuria ( P  &lt; 0.002). Only those on low dose ACEI (10 mg/day) with the I allele had increased in ESRF ( P  = 0.037). Conclusion High dose ARB is more efficacious in reducing proteinuria and preserving renal function when compared with normal dose ARB and ACEI, and also obviates the genomic influence of ACE gene polymorphism on renal survival.</description><identifier>ISSN: 1871-7934</identifier><identifier>ISSN: 1877-6558</identifier><identifier>EISSN: 1871-7942</identifier><identifier>EISSN: 1877-6566</identifier><identifier>DOI: 10.1007/s11568-009-9030-8</identifier><identifier>PMID: 19319668</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Health Promotion and Disease Prevention ; Human Genetics ; Internal Medicine ; Molecular Medicine ; Public Health ; Research Article</subject><ispartof>Genomic medicine, 2008-12, Vol.2 (3-4), p.83-91</ispartof><rights>Springer Science+Business Media B.V. 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3848-9c2a36d73e5597da7604e10fa497cf6c26230455bccf4e14f5be06b33775a5263</citedby><cites>FETCH-LOGICAL-c3848-9c2a36d73e5597da7604e10fa497cf6c26230455bccf4e14f5be06b33775a5263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694861/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694861/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19319668$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Woo, Keng-Thye</creatorcontrib><creatorcontrib>Chan, Choong-Meng</creatorcontrib><creatorcontrib>Choong, Hui-Lin</creatorcontrib><creatorcontrib>Tan, Han-Kim</creatorcontrib><creatorcontrib>Foo, Marjorie</creatorcontrib><creatorcontrib>Lee, Evan J. C.</creatorcontrib><creatorcontrib>Tan, Chorh-Chuan</creatorcontrib><creatorcontrib>Lee, Grace S. L.</creatorcontrib><creatorcontrib>Tan, Seng-Hoe</creatorcontrib><creatorcontrib>Vathsala, A.</creatorcontrib><creatorcontrib>Lim, Cheng-Hong</creatorcontrib><creatorcontrib>Chiang, Gilbert S. C.</creatorcontrib><creatorcontrib>Fook-Chong, Stephanie</creatorcontrib><creatorcontrib>Yi, Zhao</creatorcontrib><creatorcontrib>Tan, H. B.</creatorcontrib><creatorcontrib>Wong, Kok-Seng</creatorcontrib><title>High dose Losartan and ACE gene polymorphism in IgA nephritis</title><title>Genomic medicine</title><addtitle>HUGO J</addtitle><addtitle>Genomic Med</addtitle><description>Background/aims Several studies have reported varying results of the influence of ACE gene on ACEI/ARB therapy. The efficacy of high dose ARB and its influence on ACE gene have not been explored. This is a 6 year randomised trial in IgA nephritis comparing high dose ARB (Losartan 200 mg/day) with normal dose ARB (Losartan 100 mg/day), normal dose ACEI (20 mg/day) and low dose ACEI (10 mg/day). Results Patients on high dose ARB had significantly lower proteinuria, 1.0 ± 0.8 gm/day compared to 1.7 ± 1.0 g/day in the other groups ( P  = 0.0005). The loss in eGFR was 0.7 ml min −1 year −1 for high dose ARB compared to 3.2–3.5 ml min −1 year −1 for the other three groups ( P  = 0.0005). There were more patients on high dose ARB with improvement in eGFR compared to other three groups ( P  &lt; 0.001). Comparing patients with the three ACE genotypes DD, ID and II, all three groups responded well to therapy with decrease in proteinuria ( P  &lt; 0.002). Only those on low dose ACEI (10 mg/day) with the I allele had increased in ESRF ( P  = 0.037). Conclusion High dose ARB is more efficacious in reducing proteinuria and preserving renal function when compared with normal dose ARB and ACEI, and also obviates the genomic influence of ACE gene polymorphism on renal survival.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Health Promotion and Disease Prevention</subject><subject>Human Genetics</subject><subject>Internal Medicine</subject><subject>Molecular Medicine</subject><subject>Public Health</subject><subject>Research Article</subject><issn>1871-7934</issn><issn>1877-6558</issn><issn>1871-7942</issn><issn>1877-6566</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kUtLAzEYRYMovn-AGwm4cDWadyYLhVJ8QcGNrkOayUwjM8mYtIL_3kiLL3CVwD3fTT4OACcYXWCE5GXGmIu6QkhVClFU1VtgH9cSV1Ixsv11p2wPHOT8ghCXHMldsIcVxUqIeh9c3ftuAZuYHZzFbNLSBGhCAyfTG9i54OAY-_chpnHh8wB9gA_dBAY3LpJf-nwEdlrTZ3e8OQ_B8-3N0_S-mj3ePUwns8rSmtWVssRQ0UjqOFeyMVIg5jBqDVPStsISQShinM-tbUvAWj53SMwplZIbTgQ9BNfr3nE1H1xjXVgm0-sx-cGkdx2N17-T4Be6i2-aCMVqgUvB-aYgxdeVy0s9-Gxd35vg4iprSSkhjHBVyLM_5EtcpVC201hSLJXCnBYKrymbYs7JtV9_wUh_utFrN7q40Z9udF1mTn8u8T2xkVEAsgZyiULn0o-n_239AEb9mEU</recordid><startdate>200812</startdate><enddate>200812</enddate><creator>Woo, Keng-Thye</creator><creator>Chan, Choong-Meng</creator><creator>Choong, Hui-Lin</creator><creator>Tan, Han-Kim</creator><creator>Foo, Marjorie</creator><creator>Lee, Evan J. C.</creator><creator>Tan, Chorh-Chuan</creator><creator>Lee, Grace S. L.</creator><creator>Tan, Seng-Hoe</creator><creator>Vathsala, A.</creator><creator>Lim, Cheng-Hong</creator><creator>Chiang, Gilbert S. C.</creator><creator>Fook-Chong, Stephanie</creator><creator>Yi, Zhao</creator><creator>Tan, H. B.</creator><creator>Wong, Kok-Seng</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>Springer Netherlands</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200812</creationdate><title>High dose Losartan and ACE gene polymorphism in IgA nephritis</title><author>Woo, Keng-Thye ; Chan, Choong-Meng ; Choong, Hui-Lin ; Tan, Han-Kim ; Foo, Marjorie ; Lee, Evan J. C. ; Tan, Chorh-Chuan ; Lee, Grace S. L. ; Tan, Seng-Hoe ; Vathsala, A. ; Lim, Cheng-Hong ; Chiang, Gilbert S. C. ; Fook-Chong, Stephanie ; Yi, Zhao ; Tan, H. B. ; Wong, Kok-Seng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3848-9c2a36d73e5597da7604e10fa497cf6c26230455bccf4e14f5be06b33775a5263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Health Promotion and Disease Prevention</topic><topic>Human Genetics</topic><topic>Internal Medicine</topic><topic>Molecular Medicine</topic><topic>Public Health</topic><topic>Research Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Woo, Keng-Thye</creatorcontrib><creatorcontrib>Chan, Choong-Meng</creatorcontrib><creatorcontrib>Choong, Hui-Lin</creatorcontrib><creatorcontrib>Tan, Han-Kim</creatorcontrib><creatorcontrib>Foo, Marjorie</creatorcontrib><creatorcontrib>Lee, Evan J. C.</creatorcontrib><creatorcontrib>Tan, Chorh-Chuan</creatorcontrib><creatorcontrib>Lee, Grace S. L.</creatorcontrib><creatorcontrib>Tan, Seng-Hoe</creatorcontrib><creatorcontrib>Vathsala, A.</creatorcontrib><creatorcontrib>Lim, Cheng-Hong</creatorcontrib><creatorcontrib>Chiang, Gilbert S. C.</creatorcontrib><creatorcontrib>Fook-Chong, Stephanie</creatorcontrib><creatorcontrib>Yi, Zhao</creatorcontrib><creatorcontrib>Tan, H. B.</creatorcontrib><creatorcontrib>Wong, Kok-Seng</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Genomic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Woo, Keng-Thye</au><au>Chan, Choong-Meng</au><au>Choong, Hui-Lin</au><au>Tan, Han-Kim</au><au>Foo, Marjorie</au><au>Lee, Evan J. C.</au><au>Tan, Chorh-Chuan</au><au>Lee, Grace S. L.</au><au>Tan, Seng-Hoe</au><au>Vathsala, A.</au><au>Lim, Cheng-Hong</au><au>Chiang, Gilbert S. C.</au><au>Fook-Chong, Stephanie</au><au>Yi, Zhao</au><au>Tan, H. B.</au><au>Wong, Kok-Seng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High dose Losartan and ACE gene polymorphism in IgA nephritis</atitle><jtitle>Genomic medicine</jtitle><stitle>HUGO J</stitle><addtitle>Genomic Med</addtitle><date>2008-12</date><risdate>2008</risdate><volume>2</volume><issue>3-4</issue><spage>83</spage><epage>91</epage><pages>83-91</pages><issn>1871-7934</issn><issn>1877-6558</issn><eissn>1871-7942</eissn><eissn>1877-6566</eissn><abstract>Background/aims Several studies have reported varying results of the influence of ACE gene on ACEI/ARB therapy. The efficacy of high dose ARB and its influence on ACE gene have not been explored. This is a 6 year randomised trial in IgA nephritis comparing high dose ARB (Losartan 200 mg/day) with normal dose ARB (Losartan 100 mg/day), normal dose ACEI (20 mg/day) and low dose ACEI (10 mg/day). Results Patients on high dose ARB had significantly lower proteinuria, 1.0 ± 0.8 gm/day compared to 1.7 ± 1.0 g/day in the other groups ( P  = 0.0005). The loss in eGFR was 0.7 ml min −1 year −1 for high dose ARB compared to 3.2–3.5 ml min −1 year −1 for the other three groups ( P  = 0.0005). There were more patients on high dose ARB with improvement in eGFR compared to other three groups ( P  &lt; 0.001). Comparing patients with the three ACE genotypes DD, ID and II, all three groups responded well to therapy with decrease in proteinuria ( P  &lt; 0.002). Only those on low dose ACEI (10 mg/day) with the I allele had increased in ESRF ( P  = 0.037). Conclusion High dose ARB is more efficacious in reducing proteinuria and preserving renal function when compared with normal dose ARB and ACEI, and also obviates the genomic influence of ACE gene polymorphism on renal survival.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>19319668</pmid><doi>10.1007/s11568-009-9030-8</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1871-7934
ispartof Genomic medicine, 2008-12, Vol.2 (3-4), p.83-91
issn 1871-7934
1877-6558
1871-7942
1877-6566
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2694861
source SpringerLink Journals; Springer Nature OA Free Journals; PubMed Central
subjects Biomedical and Life Sciences
Biomedicine
Health Promotion and Disease Prevention
Human Genetics
Internal Medicine
Molecular Medicine
Public Health
Research Article
title High dose Losartan and ACE gene polymorphism in IgA nephritis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T11%3A38%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20dose%20Losartan%20and%20ACE%20gene%20polymorphism%20in%20IgA%20nephritis&rft.jtitle=Genomic%20medicine&rft.au=Woo,%20Keng-Thye&rft.date=2008-12&rft.volume=2&rft.issue=3-4&rft.spage=83&rft.epage=91&rft.pages=83-91&rft.issn=1871-7934&rft.eissn=1871-7942&rft_id=info:doi/10.1007/s11568-009-9030-8&rft_dat=%3Cproquest_pubme%3E733224259%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1731799153&rft_id=info:pmid/19319668&rfr_iscdi=true